[go: up one dir, main page]

DE69428795D1 - Phosphazene und polyelektrolyte als immunadjuvantien - Google Patents

Phosphazene und polyelektrolyte als immunadjuvantien

Info

Publication number
DE69428795D1
DE69428795D1 DE69428795T DE69428795T DE69428795D1 DE 69428795 D1 DE69428795 D1 DE 69428795D1 DE 69428795 T DE69428795 T DE 69428795T DE 69428795 T DE69428795 T DE 69428795T DE 69428795 D1 DE69428795 D1 DE 69428795D1
Authority
DE
Germany
Prior art keywords
polyelectrolyte
immuna
phosphazene
adjuvants
pendant groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428795T
Other languages
English (en)
Other versions
DE69428795T2 (de
Inventor
K Andrianov
A Jenkins
G Payne
E Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parallel Solutions Inc Cambridge Mass Us
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Publication of DE69428795D1 publication Critical patent/DE69428795D1/de
Application granted granted Critical
Publication of DE69428795T2 publication Critical patent/DE69428795T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C08G79/025Polyphosphazenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
DE69428795T 1993-07-12 1994-07-08 Phosphazene und polyelektrolyte als immunadjuvantien Expired - Lifetime DE69428795T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/090,841 US5562909A (en) 1993-07-12 1993-07-12 Phosphazene polyelectrolytes as immunoadjuvants
PCT/US1994/007665 WO1995002415A1 (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants

Publications (2)

Publication Number Publication Date
DE69428795D1 true DE69428795D1 (de) 2001-11-29
DE69428795T2 DE69428795T2 (de) 2002-06-13

Family

ID=22224581

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428795T Expired - Lifetime DE69428795T2 (de) 1993-07-12 1994-07-08 Phosphazene und polyelektrolyte als immunadjuvantien

Country Status (16)

Country Link
US (3) US5562909A (de)
EP (1) EP0710117B1 (de)
JP (1) JPH09500629A (de)
KR (2) KR100352336B1 (de)
CN (1) CN1134265C (de)
AT (1) ATE207505T1 (de)
AU (1) AU691824B2 (de)
BR (1) BR9407051A (de)
CA (1) CA2166208C (de)
DE (1) DE69428795T2 (de)
DK (1) DK0710117T3 (de)
ES (1) ES2166376T3 (de)
NZ (1) NZ269396A (de)
PT (1) PT710117E (de)
SG (1) SG46659A1 (de)
WO (2) WO1995002415A1 (de)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5855895A (en) * 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
AU738698B2 (en) * 1994-07-08 2001-09-27 Avant Immunotherapeutics, Inc. Polyphosphazene polyelectrolyte immunoadjuvants
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5891444A (en) * 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
CA2202928A1 (en) * 1995-08-17 1997-02-27 Wilhelmus Everhardus Hennink Poly(organo)phosphazenes for use in synthetic transfection systems
JP2000500744A (ja) * 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化dna
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5898062A (en) * 1996-04-10 1999-04-27 The Penn State Research Foundation Poly (organophosphazene) hydrogels
US5807757A (en) * 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
US6303300B1 (en) * 1996-08-16 2001-10-16 Introgen B.V. Poly (organo) phosphazenes for use in synthetic transfection systems
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
AU7563798A (en) * 1997-04-30 1998-11-24 Emory University Methods and compositions for administering dna to mucosal surfaces
US6077916A (en) * 1997-06-04 2000-06-20 The Penn State Research Foundation Biodegradable mixtures of polyphoshazene and other polymers
US5760271A (en) * 1997-08-18 1998-06-02 Virus Research Institute, Inc. Production of polyorganophosphazenes
DE69831415T2 (de) * 1997-08-29 2006-06-29 Corixa Corp., Seattle Schnellfreisetzende enkapsulierte bioaktive wirkstoffe zur induzierung einer immunantwort und verwendung derselben
US5958414A (en) * 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
US6726934B1 (en) 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
WO1999018934A1 (en) * 1997-10-09 1999-04-22 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6207171B1 (en) * 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
WO1999058134A1 (en) * 1998-05-11 1999-11-18 Purdue Research Foundation Methods and compositions for nucleic acid delivery
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US7087236B1 (en) * 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6696089B2 (en) 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
WO2000035481A2 (en) * 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6586501B1 (en) 1999-01-20 2003-07-01 Cabot Corporation Aggregates having attached polymer groups and polymer foams
US6258864B1 (en) 1999-01-20 2001-07-10 Cabot Corporation Polymer foam containing chemically modified carbonaceous filler
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
EP1194128A2 (de) 1999-06-23 2002-04-10 Sedum Laboratories Ionisch formulierte mikroträger für biomoleküle
EP2280020B1 (de) * 1999-06-29 2016-02-17 MannKind Corporation Pharmazeutische zusammensetzungen enthaltend ein peptid welches mit diketopiperazin komplexiert ist.
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
AU7085400A (en) * 1999-09-02 2001-03-26 Antigenics, Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
GB0000001D0 (en) * 2000-01-05 2000-02-23 Du Pont Uk Pharmaceutical compositions and their preparation
ATE350077T1 (de) 2000-04-11 2007-01-15 Polyzenix Gmbh Verwendung von folien aus poly-tri-fluor- ethoxypolyphosphazenen zur umhüllung von medizinischen vorrichtungen
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
PT1282702E (pt) 2000-05-10 2007-02-28 Ludwig Inst Cancer Res Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
WO2002002673A1 (en) * 2000-06-29 2002-01-10 The Penn State Research Foundation Linear polyphosphazenes and gel polymer electrolytes containing same
US6740409B1 (en) * 2000-11-15 2004-05-25 Board Of Trustees Of University Of Illinois Polymer films
DE10100961B4 (de) 2001-01-11 2005-08-04 Polyzenix Gmbh Körperverträglicher Werkstoff und mit diesem Werkstoff beschichtetes Substrat für die Züchtung von Zellen und künstlichen aus Zellen aufgebauten oder gewachsenen organischen Implantaten
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
ES2178961B1 (es) * 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
EP1417236A4 (de) * 2001-07-10 2010-03-17 Corixa Corp Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel
PT1432380E (pt) 2001-08-17 2007-01-31 Polyzenix Gmbh Dispositivo com base em nitinol com cobertura com um polifosfazeno
AU2002365414A1 (en) * 2001-11-29 2003-06-10 Parallel Solutions, Inc. Copolymer libraries and production and use thereof
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
CA2479920A1 (en) * 2002-03-29 2003-10-09 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
DE10224352A1 (de) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
US20080226723A1 (en) * 2002-07-05 2008-09-18 Celonova Biosciences, Inc. Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same
AU2003269904A1 (en) * 2002-07-10 2004-01-23 The Ohio State University Research Foundation Antigen-polymer compositions
US20040161470A1 (en) * 2002-11-22 2004-08-19 Alexander Andrianov Preparation of polyphosphazene microspheres
US20040131631A1 (en) * 2002-11-22 2004-07-08 Alexander Andrianov Polyphosphazene immunostimulants
ITMI20031617A1 (it) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus Microcapsule a doppio strato di polisaccaridi utilizzabili
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
ATE449161T1 (de) * 2004-03-04 2009-12-15 Leukocare Ag Leukozytenstimulations-matrix
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7074256B2 (en) * 2004-05-13 2006-07-11 Battelle Energy Alliance, Llc Phosphazene membranes for gas separations
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
EP1811979B1 (de) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Mikrokapseln mit einem methylxanthin und einem kortikosteroid
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
DE602005027229D1 (de) * 2004-10-25 2011-05-12 Celonova Biosciences Germany Gmbh Beladbare polyphosphazenhaltige teilchen für therapeutische und/oder diagnostische anwendungen sowie herstellungs- und verwendungsverfahren dafür
US20060193820A1 (en) * 2005-02-18 2006-08-31 Andrianov Alexander K Immunostimulating polyphosphazene compounds
US8741454B2 (en) * 2005-03-29 2014-06-03 Toyota Motor Engineering & Manufacturing North America, Inc. Proton exchange membrane for fuel cell
MX381952B (es) 2005-09-14 2025-03-13 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
KR100784485B1 (ko) * 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
JP5599975B2 (ja) 2006-02-22 2014-10-01 マンカインド コーポレイション ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドsod1媒介疾患を処置および検出するための方法および組成物
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
ES2378905T3 (es) 2006-10-10 2012-04-19 Celonova Biosciences, Inc. Válvula cardiaca bioprotésica con polifosfaceno
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
EP2155834A2 (de) * 2007-05-18 2010-02-24 Higher Dimension Materials, Inc. Flammhemmendes und flexibles wärmeschutzmaterial mit intumeszierenden schutzplatten und herstellungsverfahren dafür
US20090016935A1 (en) * 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
EP2173431A4 (de) * 2007-07-09 2013-06-12 Apogee Technology Inc Immunstimulierende polyphosphazen-verbindungen zur intradermalen immunisierung
EP2195018B1 (de) 2007-09-11 2014-11-12 University Of Guelph Polysaccharid-immunogene aus clostridium difficile
KR20160005378A (ko) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 a 및 b를 포함하는 약학적 조성물
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
US20090110738A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same
EP2212350B1 (de) 2007-10-26 2013-08-28 Governing Council of the University of Toronto Behandlung chronischer viraler Infektionen mit TIM-3 als therapeutischen Zielmolekül
US20090110731A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same
US20090110730A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same
KR101762089B1 (ko) 2008-06-13 2017-07-26 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
HUE028497T2 (en) 2008-10-16 2016-12-28 The Univ Of Saskatchewan Combination adjuvant composition
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2421505A4 (de) * 2009-04-22 2014-01-01 Univ Texas Hydrogele für die kombinatorische freisetzung von immunmodulierenden biomolekülen
JP5640079B2 (ja) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドSigmoid Pharma Limited 油滴含有組成物
MX2011013312A (es) 2009-06-12 2012-01-25 Mankind Corp Microparticulas de dicetopiperazina con areas de superficie especificas definidas.
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP2496295A1 (de) 2009-11-03 2012-09-12 MannKind Corporation Vorrichtung und verfahren zur simulation von einatmungsanstrengungen
EP2498764B1 (de) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmentierte hydrogele
CA2780294C (en) 2009-11-09 2018-01-16 Spotlight Technology Partners Llc Polysaccharide based hydrogels
US9252455B1 (en) * 2010-04-14 2016-02-02 Hrl Laboratories, Llc Lithium battery structures employing composite layers, and fabrication methods to produce composite layers
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
CN102219911B (zh) * 2011-04-28 2012-10-17 北京化工大学 一种可注射聚膦腈/明胶复合水凝胶及其制备方法
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
AU2013210783B2 (en) * 2012-01-20 2017-12-07 Cellvax Therapeutics Inc. Autologous cancer cell vaccine
EP2809347A1 (de) 2012-02-01 2014-12-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Immunogene campylobacter-zusammensetzungen und verwendungen davon
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
CN103110941B (zh) * 2012-10-09 2014-09-03 江苏康为世纪生物科技有限公司 一种新型免疫佐剂及快速免疫方案
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
EP3021834A1 (de) 2013-07-18 2016-05-25 MannKind Corporation Hitzestabile pharmazeutische trockenpulverzusammensetzungen und verfahren
EP3030294B1 (de) 2013-08-05 2020-10-07 MannKind Corporation Insufflationsvorrichtung
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3185896B1 (de) 2014-06-20 2025-04-02 University of Saskatchewan Exotoxin/thermolysinzusammensetzungen sowie verfahren und verwendung zur vorbeugung und behandlung von hufrehe
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3215127B1 (de) 2014-11-07 2020-10-28 Sublimity Therapeutics Limited Cyclosporin enthaltende zusammensetzungen
KR101762003B1 (ko) 2015-07-16 2017-07-26 연세대학교 산학협력단 경구용 바이러스 백신 전달체
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
EP3377560A4 (de) * 2015-11-18 2019-07-17 University of Maryland, College Park Polyphosphazene, verfahren zur herstellung und verwendung davon
US10858483B2 (en) * 2016-07-06 2020-12-08 University Of Maryland, College Park Polyphosphazene polyelectrolytes and uses thereof
EP3484919A4 (de) 2016-07-18 2020-03-04 The University of British Columbia Antikörper gegen amyloid beta
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US11351249B2 (en) * 2018-03-13 2022-06-07 Capsular Technologies Pty Ltd Vaccine compositions comprising a water-in-oil emulsion, immunogen-loaded hydrogel particles, and cationic polymer
US11397282B1 (en) 2018-06-29 2022-07-26 Hrl Laboratories, Llc Infrared-transparent polymer optics and methods of making and using the same
CN113271966A (zh) * 2019-01-10 2021-08-17 首尔大学校产学协力团 含有水凝胶包封的灭活细胞的口服疫苗组合物
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
MX2022013152A (es) 2020-04-20 2023-02-09 Univ Saskatchewan Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3893980A (en) * 1974-03-29 1975-07-08 Pennsylvania Res Corp Poly(amino acid alkyl ester phosphazenes)
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4055520A (en) * 1976-07-14 1977-10-25 Armstrong Cork Company Polyphosphazene blends
US4026839A (en) * 1976-08-30 1977-05-31 Armstrong Cork Company Polyphosphazene polymer/silicone rubber blends and foams therefrom
US4209014A (en) * 1977-12-12 1980-06-24 Canadian Patents And Development Limited Dispensing device for medicaments
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4495174A (en) * 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
US4636387A (en) * 1982-06-21 1987-01-13 Research Corporation Anesthetic polyorganophosphazenes
US4451647A (en) * 1982-06-21 1984-05-29 Research Corporation Heparinized polyorganophosphazenes
US4440921A (en) * 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4880622A (en) * 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
US4975280A (en) * 1989-01-23 1990-12-04 Ethyl Corporation Bioerodable sustained release implants
US4946938A (en) * 1989-08-01 1990-08-07 The University Of Pittsburgh A process for the catalytic synthesis of polyphosphazenes
US5104947A (en) * 1989-08-07 1992-04-14 Ethyl Corporation Polyphosphazenes and their synthesis
US5053451A (en) * 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
JPH06500405A (ja) * 1991-05-14 1994-01-13 ブルースカイ リサーチ インコーポレイテッド 動的シアリング干渉計

Also Published As

Publication number Publication date
EP0710117A4 (de) 1996-08-07
CA2166208C (en) 2010-04-20
ATE207505T1 (de) 2001-11-15
SG46659A1 (en) 1998-02-20
DK0710117T3 (da) 2002-02-18
DE69428795T2 (de) 2002-06-13
KR100353496B1 (ko) 2003-03-03
CN1134265C (zh) 2004-01-14
BR9407051A (pt) 1996-08-13
EP0710117A1 (de) 1996-05-08
CA2166208A1 (en) 1995-01-26
US5529777A (en) 1996-06-25
CN1128954A (zh) 1996-08-14
AU7326194A (en) 1995-02-13
ES2166376T3 (es) 2002-04-16
PT710117E (pt) 2002-04-29
AU691824B2 (en) 1998-05-28
KR960703617A (ko) 1996-08-31
KR100352336B1 (ko) 2003-04-16
US5562909A (en) 1996-10-08
US5494673A (en) 1996-02-27
JPH09500629A (ja) 1997-01-21
EP0710117B1 (de) 2001-10-24
WO1995002628A1 (en) 1995-01-26
WO1995002415A1 (en) 1995-01-26
KR960703620A (ko) 1996-08-31
NZ269396A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
DE69428795D1 (de) Phosphazene und polyelektrolyte als immunadjuvantien
BR9506590A (pt) Filmes biodegradáveis de copolímero de 3-hidroxibutirato/3-polihidroxihexanoato
ES2195656T3 (es) Peliculas que comprenden copolimeros pha biodegradables.
DK0613693T3 (da) Kvældbare sårforbindingsmaterialer
MX9201734A (es) Polimero superabsorbente que tiene propiedades mejoradas de absorbencia
CA2252607A1 (en) Medical devices with improved elastic response
MX9207284A (es) Copolimeros para elaborar aparatos biomedicos.
ATE325148T1 (de) Bioabbaubare polyhydroxyalkanoat (pha) copolymere
DE3765146D1 (de) Vernetzte karboxylgruppen enthaltende kopolymere, verwendbar als verdickungsmittel in waessrigen systemen und deren herstellung.
BR9802609A (pt) Composição, e, processo para preparar um polìmero hase neutralizado.
MX9305040A (es) Resina de autoentrelazamiento.
ATE239042T1 (de) Wasserlösliches arabinogalactan, das mit lipophilen gruppen derivatisiert ist
DE69721496D1 (de) Pektinfasern
PE20001479A1 (es) Articulos plasticos que comprenden copolimeros de polihidroxialcanoatos (pha) biodegradables
ATE304557T1 (de) Einführung von funktionellen gruppen an polymeren
BR9510286A (pt) Adjuvante para vacinas vacina utilização de um polímero e processo para preparar uma vacina
ES2089131T3 (es) Dispersiones estables de copolimeros acrilicos.
JPS536394A (en) Functional high polymers
ES2137557T3 (es) Procedimiento para el acabado por coagulacion de polimeros.
ES2074418T3 (es) Procedimiento para la solubilizacion de la poli(1-3)glucopiranosa.
MX9301818A (es) Polimeros orto que tienen estabilidad mejorada y comportamiento de biodegradacion.
CO4230030A1 (es) Proceso para preparar polisuccinimidas utilizando un secador de plato giratorio
AU4876990A (en) Cross-linked hydrogels and their use as wound dressings

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PARALLEL SOLUTIONS, INC., CAMBRIDGE, MASS., US